All right, good afternoon. My name is Bart. I'm the CEO and founder of Stantit. We're a medical device company based in the Netherlands, and we're producing and developing the first of its kind stand that not only opens the artery, but also has the capacity to reconstruct the new artery from the inside out. As a first target indication, we focus on patients that suffer from a progressive form of peripheral artery disease called chronic lymph threatening eskeeia. And these patients they have oluded blood vessels in the lower part of the foot. And if these patients are not being treated well uh they develop breast pain, they have difficulties to walk. They start developing non-healing wounds, ulcers and eventually gang green. And unfortunately still today a quarter of these patients are facing an amputation. And this is something that we want to uh that we want to resolve. There are about three and a half million patients in the EU and in the US that suffer from this disease. And there are still 250,000 annual amputations being performed. Way too many. And the cost of an amputation is not that cheap either. It's costing over $640,000 per per patient over the whole lifetime of a patient, which is almost double the amount of a limb saving procedure. Also, it's a growing market opportunity at 8.6% per year. So, what we developed is the resorbable fibrillated scaffold abbreviated the RFS. And in this animation, you can see how the how the device is working. So it can be advanced by making use of conventional guide wire and balloon catheter systems. So it's a balloon expandable stand. But what you may appreciate is that upon inflation of the balloon, the stent fixate itself into the artery. But the device does not look like any conventional stand. The device is fully and only composed of bioresolvable fibers that allow your circulating blood cells to infiltrate into the mesh. and the interaction with your immune system with this mesh is triggering a natural healing response by which we are able to reconstruct a new living artery inside the existing artery. The process takes about 3 months and then over the course of 12 months the little nanop fibers they safely dissolve from the body and in that way we uh we can reconstruct an artery uh without leaving any foreign material So the key B on the on the technology is about this process. It's about how to go from a large from a small to a large diameter without the need of a a strut pattern design. And in this uh video you can also see how the fibers reorganize upon inflation of the balloon. So this core patent has been granted in a in a majority uh major regions and also we have a strong portfolio base also to cover all aspects in the process of the What we try to achieve is that if we can show that in this space in the below the knee space the technology is working we want to further advance and also look for other indications not only to focus on stenotic indications where you have to open the artery but also think about dilated anorisms where you can rebuild a new artery inside the existing artery. But first things first the first target indication is for the below the knee segment. And in this uh next slide you can see uh some preclinical work that we did. So on the left hand side you can see minimally invasive imaging that we did uh on the 12-mon expplant and here you can see how the implant after 12 months really nicely integrated with the native tissue. On the middle panel you can see two very important protective barriers that are there in in healthy arteries that we are able to reconstruct. One is elastin. It's important to prevent neoinimal hypoplasia one of the major key failure modes for stance today. And on the right hand side endothelialization which is a very important protective barrier that should be there to prevent thrombosis. And on the right panel you can see how over time the implant gradually resorb over the course of 12 months. I'm also happy to uh to share that we started the uh the clinical initial feasibility study in gratz in Austria where we will enroll up to 10 patients. Uh the study is ongoing. We kicked off before the summer and so far the results are are looking very good. So knock on wood. uh we will keep on following these patients for a total of 24 months uh where the primary safety uh endpoint has been reached after 30 days. So here you can see uh some of the early data of the first patient that has been treated which data also has been presented at a renowned uh conference in the US in AM and on the left hand side you can see uh where the the initial stenosis was uh was there and on the right hand side after the placement of the device and these patients they are really sick they have ruford class 5 so they really have wounds that need to be treated and these patients are in need for an improved treatment option. The downside if you look at the competition um is that the majority of these patients they have really long lesions that need to be treated. So the segment can really run from your knee to your ankle and anything in between. But if you look at what the competition has developed so far and Abbott is the only one with the FDA approved device in the US they have very short segments that they can treat with a single device. So in order to treat the majority of these patients they need to implant multiple devices in parallel to each other. And that's not only creating a cost uh cost burden for the healthcare system but also it has limitations as well. Um what we try to achieve with our device is to make longer devices up to 150 mm in length as the first phase and gradually expand to longer phases as well. And the reason why we think we can do this is that we do not need to elude the drug. Our device is is triggering a natural healing response for which we can stay away from drug illusion and therefore you do not run into the toxicity issues that the competition is facing. Also by stay away from a drug illusion we have rapid tissue integration. So long devices are integrated really well with the native tissue without having any risk of distal embleization. And also since it's made out of fibers the flow profile is very favorable also to support endothelialization for the longer devices. Next to myself as a technical founder, I also are privileged to have my colleague Golo next to me as chief operating officer to go from a prototype to a product that we have today. Also chief medical officer as we are going more into the clinical stage. Strong business advisor to help on venture building market access and also on the in industrialization. A good key opinion leader and a very interdisciplinary medical advisory board that is supportive as well. So what are we up to now? So uh we want to complete the study by year end. uh which data we hope to be available by year end as well. Um and as we are uh further down the road, we want to extend the size matrix really to go up to 150 mm in length. And with that data, we are preparing for a combined randomized control clinical trial uh that will run in the EU and in the US. And for this next phase, we are raising a minimum uh close of 30 million. And from this 30 10 is already been committed by the European Investment Bank through the ESC Accelerator program. We have 15 million in soft commitments but we are still looking for a lead that can support the valuation of the company and that can support us with closing this round. Um and with that I would like to thank you for your